Clinical Trial Update: Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in children with intermediate and high-risk rhabdomyosarcoma using liposomal irinotecan-based therapy guided by molecular risk stratifi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhabdomyosarcoma

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Rhabdomyosarcoma | Phase 2 | Status: RECRUITING